A Phase 2 interventional study of imatinib mesylate in Glioblastoma, sponsored by Novartis. Terminated at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-24.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing imatinib in Glioblastoma — none open to participants now, none under way, none of them phase 3. imatinib · Glioblastoma.
Among the 10 studies testing imatinib in Glioblastoma, this one is the 7th largest by enrollment, is one of 3 that started in 2004, is one of 5 in phase 2, and was the 4th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →None of the 10 studies testing imatinib in Glioblastoma is open now. The open studies under Glioblastoma, anywhere →
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1
First in 2001; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 65 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
22 studies in Glioblastoma by Novartis: none open now, 4 under way, none of them phase 3. Of 18 finished, 8 (44%) have results posted.
Among the 22 studies in Glioblastoma by Novartis, this one is the 17th largest by enrollment, is one of 3 that started in 2004, is one of 6 in phase 2, and was the 5th registered.
Novartis’s Glioblastoma studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing imatinib in Glioblastoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 22 in Glioblastoma:
This tab as a report to print or save as PDF → With an account.
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months
Objective Tumoral Response defined by RECISt criteria performed by MRI
OS (overall survival)
Ran from Apr 2004 to primary completion in Jun 2006, 26 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib